Ensysce Biosciences(US:ENSC) Prnewswire·2025-03-03 14:43Core Insights - Ensysce Biosciences is developing safer opioids using "clever chemistry" to reduce the risks of accidental overdose and abuse [1][4][5] - The opioid crisis remains a significant issue, with approximately 3 million patients annually relying on opioids for pain management, leading to nearly one trillion dollars in economic costs to the healthcare industry [3][6] - Ensysce's modified oxycodone has received FDA "Fast Track" and "Breakthrough Therapy" designations, indicating a recognized medical need and expedited availability [6] Company Overview - Ensysce Biosciences focuses on innovative oral drug delivery solutions, utilizing proprietary technologies like TAAP™ and MPAR® to enhance patient safety by preventing abuse and overdose [8][9] - The company aims to address the dual crises of opioid pain treatment needs and regulatory restrictions on opioid use, positioning itself as a potential solution to this impasse [7] Industry Context - The pharmaceutical industry has invested heavily in alternative painkillers without success, while Ensysce's approach involves re-engineering opioids to ensure they are safer for prescription [4][5] - The ongoing opioid crisis highlights the necessity for effective pain management solutions that minimize health risks, making Ensysce's innovations particularly relevant [3][6]